In-Vision™ Imaging System is used for the qualitative and quantitative evaluation of vascular morphology in the coronary arteries and vessels of the peripheral vasculature. It is also incicated as an adjunct to conventional angiographic procedures to provide an image of vessel lumen and wall structures.

ChromaFlo is indicated for qualitative blood flow information from peripheral and coronary vaculature; flow information can be an adjunct to other methods of estimating blood flow and blood perfusion.

Device Description

The JOMED Inc. In-Vision™ Imaging System consists of the imaging catheter, the patient interface module, and the system console. The system console gathers and displays high-resolution intra'uminal images that can be analyzed both qualitatively and quantitatively. In addition to supplying diagnostic information, the In-Vision™ Imaging Systems can be adjunct to interventional therapies, such as balloon angioplasty. With ChromoFloTM, a two-dimensional color map of relative blood flow is overlaid on the grayscale image, providing a ditional information for vessel analysis. The In-Line Digital™ option displays a two-dimensional, 360° rotations, and longitudinal view of the vessel.

AI/ML Overview

Here's an analysis of the provided text regarding the In-Vision™ Imaging System's acceptance criteria and studies:

Based on the provided 510(k) summary, the document does not contain specific acceptance criteria tables or detailed performance study results in the manner requested. The submission is a "Special 510(k)" for a software modification (version upgrade to V4.1) of an existing device. For such submissions, the focus is often on demonstrating that the changes do not raise new questions of safety or efficacy, rather than presenting extensive de novo performance data.

Therefore, many of the requested fields cannot be filled directly from this document. However, I can extract the available information and highlight what is missing.

Acceptance Criteria and Device Performance

Not explicitly stated in the document. The document states: "Applicable testing was performed to evaluate the modifications to the In-Vision™ Imaging System. The test results were found to be acceptable as required by the respective test plans and protocols."

This indicates that internal acceptance criteria and protocols were used, but the specific metrics and performance values are not disclosed in this 510(k) summary.

Study Details (Based on Available Information)

Since detailed performance data is not provided, many of these sections will indicate "Not specified in document."

#	Feature	Description
1	A table of acceptance criteria and the reported device performance	Not specified in document. The document states "Applicable testing was performed... The test results were found to be acceptable as required by the respective test plans and protocols," but no specific criteria or performance values are provided.
2	Sample size used for the test set and data provenance	Not specified in document. The document does not mention sample sizes for any test sets or the origin (country, retrospective/prospective) of any data.
3	Number of experts used to establish the ground truth for the test set and qualifications	Not specified in document. No information on expert involvement or ground truth establishment is provided for any testing.
4	Adjudication method (e.g., 2+1, 3+1, none) for the test set	Not specified in document. No information on adjudication methods is present.
5	If a multi-reader multi-case (MRMC) comparative effectiveness study was done, and its effect size	Not specified in document. The document does not mention an MRMC study or any comparison of human readers with vs. without AI assistance. This device is an imaging system, not an AI-assisted diagnostic tool in the modern sense.
6	If a standalone (i.e. algorithm only without human-in-the loop performance) was done	Not specified in document. While "performance data" is mentioned, there's no detail on whether this involved standalone algorithm performance, or if the "device" implicitly includes a human operator for interpretation. Given the era and device type, it's highly likely human interpretation is integral.
7	The type of ground truth used (expert consensus, pathology, outcomes data, etc.)	Not specified in document.
8	The sample size for the training set	Not specified in document. It's unlikely a "training set" in the modern machine learning sense was employed given the context of a software modification to an intravascular ultrasound system in 2003. "Training" would more likely refer to system configuration or calibration.
9	How the ground truth for the training set was established	Not specified in document.

Summary of Information from the Document:

Device Name: In-Vision™ Imaging System
Purpose of Submission: Software modification (version upgrade to V4.1) to an existing intravascular ultrasound imaging system.
Comparison: Claims substantial equivalence to predicate devices based on fundamental scientific technology, intended use, and clinical applications.
Performance Data Statement: "Applicable testing was performed to evaluate the modifications... The test results were found to be acceptable as required by the respective test plans and protocols." This indicates internal testing was done and met predefined criteria, but the specifics are not public in this summary.
Conclusion: The software modification "raises no new questions about safety and efficacy."

This 510(k) summary focuses on demonstrating that a software update to an already cleared device does not alter its fundamental safety or effectiveness profile, rather than providing a detailed performance study as might be expected for a novel device or an AI/ML product today.

Summary

{0}------------------------------------------------

Jomed Inc.

MAY 28 2003

March 17, 2003

p.113 In-Vision™ Imaging System Special 510(k)

510 (K) Summary In-Vision™ Imaging System

Date Prepared:	January 2, 2003
Submitted by:	JOMED Inc.2870 Kilgore Rd.Rancho Cordova, CA 95670
Contact person:	Lorry W. HuffmanRegulatory Affairs Manager
Phone number:Facsimile number:	(916) 638-9404 or (800) 228-4728 ext. 404(916) 638-8112
Device Name:	In-Vis on™ Imaging System

Classification name:

892.1560 Ultrasonic pulsed echo imaging system

Class II

Predicate Device:

Cathscanner III Imaging System cleared under K944004 on May 4, 1995; ColorFlo Option for the Oracle InVision Intravascular Ultrasound Imaging System cleared under K963290 on August 6, 1997; and the Resolve Option for the Oracle InVision Intravascular Ultrasound Imaging System cleared under K965223 on June 29, 1998.

JOMED Inc. purchased Endesonics Corporation under which K944004, K963290 and K965223 were filed.

Device Description:

{1}------------------------------------------------

Jomed Inc. March 17, 2003 In-Vision™ Imaging System Special 510(k) · 213

Digital™ option displays a two-dimensional, 360° rotations, and longitudinal view of the vessel. -

The imaging catheters are all marketed under separate 510(k)'s; Visions catheters K982329, Avanar catheters K000820, and Eagle Eye F/X 2.9F pending future submission.

Intended Use:

In-Vision™ Imaging System is used for the qualitative and quantitative evaluation of vascular morphology in the coronary arteries and vessels of the peripheral vasculature. It is also indicated as an adjunct to conventional angiographic procedures to provide an image of vessel lumen and wall structures.

ChromaFlo feature is indicated for qualitative blood flow information from peripheral and coronary vaculature; flov; information can be an adjunct to other methods of estimating blood flow and blood perfusion.

Device Technological Characteristics and Comparison to Predicate Device:

The In-Vision™ Imaging System uses the same fundamental scientific technology and has the same intended use and clinical applications as that of the predicate device. This is a software modification version upgrade to V4.1.

Performance Data:

Applicable testing was performed to evaluate the modifications to the In-Vision™ Imaging System. The test results were found to be acceptable as required by the respective test plans and protocols.

Conclusion:

The In-Vision™ Imaging System has the same Intended Use and utilizes the same fundamental scientific technology as that of the predicate devices. The performance data along with the Declaration of Conformity with Design Controls support a determination of substantial equivalence of the modified device, In-Vision™ Imaging System to the

{2}------------------------------------------------

(03/148 p:3 (3

predicate devices. This software modification version upgrade to V4.1 raises no new questions about safety and efficacy.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized symbol of a human figure with three heads, representing health and well-being. The symbol is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" in a circular arrangement.

Public Health Service

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAY 28 2003

JOMED Inc. c/o Ms. Lorraine W. Huffman Regulatory Affairs Manager 2870 Kilgore Rd. Rancho Cordova, CA 95670

Re: K031148

Trade Name: In-Vision™ Imaging System Regulation Number: 21 CFR 870.2330 Regulation Name: Echocardiograph Regulatory Class: Class II (two) Product Code: DXK Dated: April 8, 2003 Received: April 10, 2003

Dear Ms. Huffman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federa! Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

{4}------------------------------------------------

Page 2 - Ms. Lorraine W. Huffman

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4646. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours.

h.
Bram D. Zuckerman, M.D.

ram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

KO31148 510(k) Number (if known):

Device Name: In-Vision™ Imaging System

Indications for Use:

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription
Use
(Per 21 CFR 801.19)

Over-the-Counter Use

ﻠﺴﻠ

(Division Sign-Off)
Division of Cardiovascular Devices

510(k) Nt

Regulation Number and Section

§ 870.2330 Echocardiograph.

(a)
Identification. An echocardiograph is a device that uses ultrasonic energy to create images of cardiovascular structures. It includes phased arrays and two-dimensional scanners.(b)
Classification. Class II (performance standards).